Evidence map›Paper›PMID 34784380›Full record

ArticlePloS one2021

Dosing intact birch pollen grains at the air-liquid interface (ALI) to the immortalized human bronchial epithelial cell line BEAS-2B.

Joana Candeias, Carsten B Schmidt-Weber, Jeroen Buters

Abstract read
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Elevated COAllergy · 2026
    Article
  2. Review
  3. Article
  4. TUBE Project: Transport-Derived Ultrafines and the Brain Effects.International journal of environmental research and public health · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Joana CandeiasCenter Allergy & Environment (ZAUM), Member of the German Center for Lung Research (DZL), Technical University Munich, Helmholtz Center Munich, Munich, Germany.ORCID 0000-0002-6239-6157
Carsten B Schmidt-WeberCenter Allergy & Environment (ZAUM), Member of the German Center for Lung Research (DZL), Technical University Munich, Helmholtz Center Munich, Munich, Germany.
Jeroen ButersCenter Allergy & Environment (ZAUM), Member of the German Center for Lung Research (DZL), Technical University Munich, Helmholtz Center Munich, Munich, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In real life, humans are exposed to whole pollen grains at the air epithelial barrier. We developed a system for in vitro dosing of whole pollen grains at the Air-Liquid Interface (ALI) and studied their effect on the immortalized human bronchial epithelial cell line BEAS-2B. Pollen are sticky and large particles. Dosing pollen needs resuspension of single particles rather than clusters, and subsequent transportation to the cells with little loss to the walls of the instrumentation i.e. in a straight line. To avoid high speed impacting insults to cells we chose sedimentation by gravity as a delivery step. Pollen was resuspended into single particles by pressured air. A pollen dispersion unit including PTFE coating of the walls and reduced air pressure limited impaction loss to the walls. The loss of pollen to the system was still about 40%. A linear dose effect curve resulted in 327-2834 pollen/cm2 (± 6.1%), the latter concentration being calculated as the amount deposited on epithelial cells on high pollen days. After whole pollen exposure, the largest differential gene expression at the transcriptomic level was late, about 7 hours after exposure. Inflammatory and response to stimulus related genes were up-regulated. We developed a whole pollen exposure air-liquid interface system (Pollen-ALI), in which cells can be gently and reliably dosed.

Indexed as

BetulaBronchiCell LineCytokinesEpithelial CellsFractionation, Field FlowGene Expression ProfilingGene Expression RegulationHumansInterleukin-17Interleukin-33PollenThymic Stromal LymphopoietinCytokinesIL25 protein, humanIL33 protein, humanInterleukin-17Interleukin-33Thymic Stromal LymphopoietinTSLP protein, human

Identifiers

PMID34784380
PMCPMC8594808

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.